Kristine Swiderek
Director/Board Member at Sitka Biopharma, Inc.
Profile
Kristine Swiderek was the founder of OncoResponse, Inc. which was founded in 2015, where she held the title of Chief Scientific Officer from 2015 to 2017.
She is currently the Director at Sitka Biopharma, Inc. since 2017.
Dr. Swiderek's former positions include Vice President-Protein Science at ZymoGenetics, Inc., Chief Scientific Officer at Theraclone Sciences, Inc. from 2011 to 2017, and Senior Vice President-Research at Alpine Immune Sciences, Inc. from 2017 to 2020.
Dr. Swiderek earned a doctorate degree from Ruhr-Universität Bochum.
Kristine Swiderek active positions
| Companies | Position | Start |
|---|---|---|
Sitka Biopharma, Inc.
 Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Director/Board Member | 2017-09-05 |
Former positions of Kristine Swiderek
| Companies | Position | End |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 2020-05-31 |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Chief Tech/Sci/R&D Officer | 2017-11-30 |
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Founder | 2017-11-30 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Training of Kristine Swiderek
| Ruhr-Universität Bochum | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Sitka Biopharma, Inc.
Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Kristine Swiderek
